Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Независимый исследователь в области психофармакологии, Израиль, Азур 5801726, ул. Бен-Гурион 26/7; 2 ФГБОУ «Ставропольский государственный медицинский университет», Российская Федерация, г. Ставрополь, 355017, ул. Мира, 310.
Список исп. литературыСкрыть список 1. Беккер РА, Быков ЮВ, Морозов ПВ. Выдающиеся психиатры ХХ века. – М.: ИД «Городец», 2019. –256 с. 2. Беккер РА, Быков ЮВ. Велаксин® в капсулах: представление новой пролонгированной формы и обзор новейших данных об эффективности и безопасности. Психиатрия и психофармакотерапия: журнал им. ПБ Ганнушкина. 2017;19(6):33. 3. Беккер РА, Быков ЮВ. Иксел®(милнаципран): уникальный антидепрессант четвертого поколения и его терапевтические возможности. Психиатрия и психофармакотерапия. 2019;21(2): 41-52. 4. Беккер РА, Быков ЮВ. Триттико (тразодон)-уникальный серотонинергический антидепрессант с рядом дополнительных свойств. Психиатрия и психофармакотерапия. 2018;20(3-4):51-62. 5. Беккер РА, Быков ЮВ. Эглонил®: замечательное триединство–атипичный антипсихотик, психосоматический препарат и антидепрессант. К 50-летию создания препарата. Психиатрия и психофармакотерапия. 2019;21(6):32-40. 6. Быков ЮВ, Беккер РА. Антидепрессанты в роли анальгетиков: в фокусе–милнаципран. Психиатрия и психофармакотерапия. 2016; 18(6):41-48. 7. Петрова НН, Морозов ПВ, Маркин АВ, Беккер РА, Быков ЮВ. Пандемия COVID-19: актуальные вызовы времени, а также новейшие данные к вопросу рационального выбора психофармакотерапии у пациентов с SARS-CoV-2. Психиатрия и психофармакотерапия. 2020;6(22):8-24. 8. Ahmed EI, Alhuwaydi AM, Taha AE, Abouelkheir M. Anti-Candidal Activity of Reboxetine and Sertraline Antidepressants: Effects on Pre-Formed Biofilms. Antibiotics (Basel). 2023;12(5):881. doi: 10.3390/antibiotics12050881 9. Alanís-Ríos SA, González GM, Andrade A et al. Evaluation of the synergistic antifungal activity of micafungin and voriconazole plus sertraline against Candida auris. Braz J Microbiol. 2022;53(4):2003-2008. doi: 10.1007/s42770-022-00817-y 10. Alhadab AA, Rhein J, Tugume L et al. Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis. J Pharmacokinet Pharmacodyn. 2019;46(6):565-576. doi: 10.1007/s10928-019-09657-0 11. Alkhalifa BA, Bulatova NR, Abu-Rokba W, Darwish RM. Serotonin reuptake inhibitors effect on fluconazole activity against resistant Candida glabrata strains. J Glob Antimicrob Resist. 2022;29:49-54. doi: 10.1016/j.jgar.2022. 01.030 12. Alves V, Araújo GR, Frases S. Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis. Future Microbiol. 2023;18:127-135. doi: 10.2217/fmb-2022-0122 13. Amsterdam JD, Maislin G, Hooper MB. Suppression of herpes simplex virus infections with oral lithium carbonate--a possible antiviral activity. Pharmacotherapy. 1996;16(6):1070-5 14. Anar MA, Foroughi E, Sohrabi E et al. Selective serotonin reuptake inhibitors: New hope in the fight against COVID-19. Front Pharmacol. 2022;13:1036093. doi: 10.3389/fphar.2022.1036093 15. Augustin Y, Staines HM, Velavan TP et al. Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews. Br Med Bull. 2023;ldac037. doi: 10.1093/bmb/ldac037 16. Baig AM, Rana Z, Tariq S et al. Traced on the Timeline: Discovery of Acetylcholine and the Components of the Human Cholinergic System in a Primitive Unicellular Eukaryote Acanthamoeba spp. ACS Chem Neurosci. 2018;9(3):494-504. doi: 10.1021/acschemneuro.7b00254 17. Barbarossa A, Rosato A, Corbo F et al. Non-Antibiotic Drug Repositioning as an Alternative Antimicrobial Approach. Antibiotics (Basel). 2022;11(6):816. doi: 10.3390/antibiotics11060816 18. Bi J, Khan A, Tang J, Armando AM et al. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021;37(5):109957. doi: 10.1016/j.celrep.2021.10995 19. Boulware DR, Nalintya E, Rajasingham R et al. Adjunctive sertraline for asymptomatic cryptococcal antigenemia: A randomized clinical trial. Med Mycol. 2020;58(8):1037-1043. doi: 10.1093/mmy/myaa033 20. Bramante CT, Buse JB, Liebovitz DM et al. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis. 2023;S1473-3099(23)00299-2. doi: 10.1016/S1473-3099(23)00299-2 21. Bschor T. Complete suppression of recurrent herpes labialis with lithium carbonate. Pharmacopsychiatry. 1999;32(4):158. doi: 10.1055/s-2007-979224 22. de Andrade Mesquita L, Piccoli GF, da Natividade GR et al. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. Obes Rev. 2021;22(3):e13170. doi: 10.1111/obr.13170 23. Decloedt EH, Freeman C, Howells F et al. Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine (Baltimore). 2016;95(46):e5401 24. Dilly SJ, Clark AJ, Marsh A et al. A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment. Cancer Lett. 2017;393:16-21. doi: 10.1016/j.canlet. 2017.01.042 25. Dimmock NJ, Easton AJ, Leppard KN. Introduction to Modern Virology. Wiley-Blackwell. 7th Ed. 2016. 544 p. ISBN 978-1119978107. 26. Doello K, Mesas C, Quiñonero F et al. Antitumor Effect of Traditional Drugs for Neurological Disorders: Preliminary Studies in Neural Tumor Cell Lines. Neurotox Res. 2022;40(6):1645-1652. doi: 10.1007/s12640-022-00606-3 27. Edmunds MW. Introduction to Clinical Pharmacology. Mosby. 8th Ed. 2015. 496 p. ISBN 978-0323187657. 28. Freestone PP. Microbial endocrinology: interkingdom signaling in infectious disease and health. Springer, 2010. 29. Furuta T, Sabit H, Dong Y et al. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma. Oncotarget. 2017;8(14):22811-22824. doi: 10.18632/oncotarget.15206 30. Gil-Ad I, Zolokov A, Lomnitski L et al. Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice. Int J Oncol. 2008;33(2):277-86. 31. Golden SR, Rosenstein DL, Belhorn T, Blatt J. Repurposing Psychotropic Agents for Viral Disorders: Beyond Covid. Assay Drug Dev Technol. 2021;19(6):373-385. doi: 10.1089/adt.2021.014 32. Halatsch ME, Dwucet A, Schmidt CJ et al. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals (Basel). 2021;14(12):1241. doi: 10.3390/ph14121241. 33. Halatsch ME, Kast RE, Dwucet A et al. Bcl-2/Bcl-xL inhibition predominantly synergistically enhances the anti-neoplastic activity of a low-dose CUSP9 repurposed drug regime against glioblastoma. Br J Pharmacol. 2019;176(18):3681-3694. doi: 10.1111/bph.14773 34. Halatsch ME, Kast RE, Karpel-Massler G et al. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neurooncol Adv. 2021;3(1):vdab075. doi: 10.1093/noajnl/vdab075. 35. Jefferson JW. Antiviral therapies for long-term suppression of genital herpes. JAMA. 1999;281(13):1170-1. 36. Kast RE, Boockvar JA, Brüning A et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013;4(4):502-30. doi: 10.18632/oncotarget.969 37. Kast RE, Karpel-Massler G, Halatsch ME. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. 2014;5(18):8052-82. doi: 10.18632/oncotarget.2408 38. Kast RE. Agomelatine or ramelteon as treatment adjuncts in glioblastoma and other M1- or M2-expressing cancers. Contemp Oncol (Pozn). 2015;19(2):157-62. doi: 10.5114/wo.2015.51421. 39. Kumar R, Ryan D. Lorcaserin Departs, Leaving More Questions than Answers. Obesity (Silver Spring). 2020;28(7):1167. doi: 10.1002/oby.22789. 40. Li W, Yun Z, Ji C et al. Discovery of Novel Sertraline Derivatives as Potent Anti- Cryptococcus Agents. J Med Chem. 2022;65(9):6541-6554. doi: 10.1021/acs.jmedchem.1c01845 41. Liu Z, Jiang X, Gao L et al. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. World Neurosurg. 2019;128:e468-e477. doi: 10.1016/j.wneu.2019.04.180 42. Magner LN, Kim OJ. A history of medicine. CRC Press. 2017. 43. Menezes RT, Pereira TC, Junqueira JC et al. Synergistic combination of duloxetine hydrochloride and fluconazole reduces the cell growth and capsule size of Cryptococcus neoformans. An Acad Bras Cienc. 2022;94(2):e 20211021. doi: 10.1590/0001-3765202220211021 44. Moreira CG, Sperandio V. The epinephrine/norepinephrine/autoinducer-3 interkingdom signaling system in Escherichia coli O157: H7. Microbial Endocrinology: Interkingdom Signaling in Infectious Disease and Health, 213-227. Springer, 2010. 45. Ngan NT, Flower B, Day JN. Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going? Drugs. 2022;82(12):1237-1249. doi: 10.1007/s40265-022-01757-5 46. Papadopoulos F, Isihou R, Alexiou GA et al. Haloperidol Induced Cell Cycle Arrest and Apoptosis in Glioblastoma Cells. Biomedicines. 2020;8(12):595. doi: 10.3390/biomedicines8120595 47. Pauletto PT, Delgado CP, da Rocha JT. Acid sphingomyelinase (ASM) and COVID-19: A review of the potential use of ASM inhibitors against SARS-CoV-2. Cell Biochem Funct. 2023;41(3):284-295. doi: 10.1002/cbf.3789 48. Puertas MC, Salgado M, Morón-López S et al. Effect of lithium on HIV-1 expression and proviral reservoir size in the CD4+ T cells of antiretroviral therapy suppressed patients. AIDS. 2014;28(14):2157-9. doi: 10.1097/ QAD.0000000000000374 49. Reizer J, Finley K, Kakuda D et al. Mammalian integral membrane receptors are homologous to facilitators and antiporters of yeast, fungi, and eubacteria. Protein Sci. 1993;2(1):20-30. doi: 10.1002/pro.5560020103 50. Rhein J, Hullsiek KH, Tugume L et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. Lancet Infect Dis. 2019;19(8):843-851. doi: 10.1016/S1473-3099(19)30127-6 51. Rhein J, Morawski BM, Hullsiek KH et al. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study. Lancet Infect Dis. 2016;16(7):809-818. doi: 10.1016/ S1473-3099(16)00074-8 52. Rocha CL, Rocha FM, Bitencourt TA. Synergism between the Antidepressant Sertraline and Caspofungin as an Approach to Minimise the Virulence and Resistance in the Dermatophyte Trichophyton rubrum. J Fungi (Basel). 2022;8(8):815. doi: 10.3390/jof8080815 53. Rybakowski JK. Antiviral, immunomodulatory, and neuroprotective effect of lithium. J Integr Neurosci. 2022;21(2):68. doi: 10.31083/j.jin2102068 54. Rybakowski JK. Lithium – past, present, future. Int J Psychiatry Clin Pract. 2020;24(4):330-340. doi: 10.1080/13651501.2020.1775855 55. Serafin MB, Bottega A, da Rosa TF et al. Drug Repositioning in Oncology. Am J Ther. 2021;28(1):e111-e117. doi: 10.1097/MJT.0000000000000906 56. Sharretts J, Galescu O, Gomatam S et al. Cancer Risk Associated with Lorcaserin – The FDA's Review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383(11):1000-1002. doi: 10.1056/NEJMp2003873 57. Shi L, Chen H, Chen K et al. The DRD2 Antagonist Haloperidol Mediates Autophagy-Induced Ferroptosis to Increase Temozolomide Sensitivity by Promoting Endoplasmic Reticulum Stress in Glioblastoma. Clin Cancer Res. 2023;29(16):3172-3188. doi: 10.1158/1078-0432.CCR-22-3971. 58. Skaga E, Skaga I, Grieg Z et al. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy. J Cancer Res Clin Oncol. 2019;145(6):1495-1507. doi: 10.1007/s00432-019-02920-4 59. Skinner GR. Lithium ointment for genital herpes. Lancet. 1983;2(8344):288. doi: 10.1016/s0140-6736(83)90275-1 60. Sneader W. Drug discovery: a history. John Wiley and Sons. 2005. doi:10.1002/0470015535 61. Stahl SM. Stahl's essential psychopharmacology: neuroscientific basis and practical applications. 5th Ed. Cambridge university press. 2021. 642 p. ISBN 978-1108838573. 62. Thela L, Decloedt E, Zetterberg H et al. Blood and cerebrospinal fluid biomarker changes in patients with HIV-associated neurocognitive impairment treated with lithium: analysis from a randomised placebo-controlled trial. J Neurovirol. 2023;29(2):156-166 63. Tuszynski J, Tilli TM, Levin M. Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer. Curr Pharm Des. 2017; 23(32): 4827-4841. doi: 10.2174/1381612823666170530105837 64. Villanueva-Lozano H, Treviño-Rangel RJ, González GM et al. Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience. Infection. 2018 Feb;46(1):25-30. doi: 10.1007/s15010-017-1059-3 65. Weissenrieder JS, Reed JL, Green MV et al. The Dopamine D2 Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma Cells. Pharmacology. 2020;105(1-2):19-27. doi: 10.1159/000502562 66. Wiklund ED, Catts VS, Catts SV et al. Cytotoxic effects of antipsychotic drugs implicate cholesterol homeostasis as a novel chemotherapeutic target. Int J Cancer. 2010;126(1):28-40. doi: 10.1002/ijc.24813 67. Yeh CT, Wu AH, Chang PM et al. Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer. Am J Respir Crit Care Med. 2012;186(11):1180-8. doi: 10.1164/rccm. 201207-1180OC 68. Zhelev Z, Ohba H, Bakalova R et al. Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes. Phenothiazines and leukemia. Cancer Chemother Pharmacol. 2004;53(3):267-75. doi: 10.1007/s00280-003-0738-1